通腑汤对急性肺损伤大鼠肺、肠组织SP的影响
摘要
目的：观察通腑汤对ALI大鼠肺、肠组织中SP的影响。探讨通腑汤对ALI的作用机制,为“肺与大肠相表里”理论提供实验依据。
方法：180只大鼠随机分正常对照组、模型组、地塞米松组、中药低剂量组、中药中剂量组和中药高剂量组,30只/组。尾静脉注射LPS复制ALI模型,半小时后中药各剂量组予高、中、低剂量中药灌胃、地塞米松组予腹腔注射地塞米松治疗。于治疗后第1、2、6小时,处死大鼠,每组每次各10只。光镜下观察肺、肠组织的形态学变化；ELISA法同步检测肺、肠组织中SP的含量。
结果：
1肉眼见模型组肺、肠组织颜色暗红、肿胀、出血,各治疗组较模型组减轻。
2光镜下见模型组肺、肠组织炎性细胞浸润、水肿、充血、结构破坏,各治疗组较模型组程度减轻。
3模型组肺组织中SP含量在前6小时内随时间的延长而增长,肠组织中SP含量随时间的延长而降低。
4模型组和正常对照组相比,肺组织中SP显著升高,肠组织中SP显著降低,有统计学意义(P<0.05)。治疗各组和模型组比,肺组织中SP下降明显,肠组织中SP升高明显,有统计学意义(P<0.05)。中药低剂量组肺组织中SP含量高于地塞米松组,肠组织中SP含量低于地塞米松组,有统计学意义(P<0.05)：中药中剂量组、中药高剂量组肺、肠组织中SP含量与地塞米松组无显著差异,无统计学意义(P>0.05)；中药中剂量组、中药高剂量组肺组织中SP含量均低于中药低剂量组,肠组织中SP含量均高于中药低剂量组,有统计学意义(P<0.05)；中药高剂量组肺、肠组织中SP含量与中药中剂量组无显著差异,无统计学意义(P>0.05)。
结论：
1通腑汤可降低ALI大鼠肺组织中SP的含量,高、中剂量组效果较好。
2通腑汤可增高ALI大鼠肠组织中SP的含量,高、中剂量组效果较好。
Objective:To observe the effect on substance P(SP) in lung and intestine tissue of ALI rat model treated by Tongfu decoction, and explore the mechanisms of Tongfu decoction anti-ALI, so to provide experimental base on the lung and the large intestine being interior-exteriorly related theory.
Methods:180 Wistar rats were divided into 6 groups randomly:the normal control group, the model group, hexadecadrol group, Chinese herbal medicine low-dose group, medium-dose group, and high-dose group,30 rats each group. Copying ALI model by caudal vein injecting LPS, giving respectively the Chinese herbal medicine intragastric administration and Dexamethasone intraperitoneal injection half an hour later, and executing rats in 1,2,6 hour after treatment respectively,10 rats each time in each group. We observed lung and intestine histomorphology changes, detected SP content in lung and intestine by ELISA method synchronously.
Result:
1 Lung and intestine tissue in the model group showed dark red, turgent, bleeding by naked eye, but other treatment groups showed lighter than it.
2 Lung and intestine tissue in the model group showed inflammatory cell infiltrating, edema, hyperemia, disorganization in light microscope, but other treatment groups showed lighter.
3 SP content increased in lung tissue of the model group, while it decreased in intestine tissue as time extending in first 6 hours.
4 Compared with normal control group, There was higher SP expression in lung tissue and lower SP expression in intestine tissue in model group (P<0.05). SP decreased in lung tissue and increased in intestine tissue significantly in treatment groups Compared with model group (P<0.05). Compared with dexamethasone group,SP level is higher in lung tissue and lower in intestine tissue in low-dose group (P<0.05).In high-dose group、medium-dose group and dexamethasone group,SP level in lung and intestine tissue was similar, which showed no significant deviation (P>0.05). SP in low-dose group is higher in lung tissue and lower in intestine than high-dose and medium-dose group (P<0.05). In high-dose group、medium-dose group,SP level in lung and intestine tissue was similar, which showed no significant deviation (P>0.05).
Conclusion:
1 Tongfu Decoction could decrease SP in lung tissue of ALI rats model, the high-dose and medium-dose group showed better effects.
2 Tongfu Decoction could increase SP in intestine tissue of ALI rats model, the high-dose and medium-dose group showed better effects.
方法：180只大鼠随机分正常对照组、模型组、地塞米松组、中药低剂量组、中药中剂量组和中药高剂量组,30只/组。尾静脉注射LPS复制ALI模型,半小时后中药各剂量组予高、中、低剂量中药灌胃、地塞米松组予腹腔注射地塞米松治疗。于治疗后第1、2、6小时,处死大鼠,每组每次各10只。光镜下观察肺、肠组织的形态学变化；ELISA法同步检测肺、肠组织中SP的含量。
结果：
1肉眼见模型组肺、肠组织颜色暗红、肿胀、出血,各治疗组较模型组减轻。
2光镜下见模型组肺、肠组织炎性细胞浸润、水肿、充血、结构破坏,各治疗组较模型组程度减轻。
3模型组肺组织中SP含量在前6小时内随时间的延长而增长,肠组织中SP含量随时间的延长而降低。
4模型组和正常对照组相比,肺组织中SP显著升高,肠组织中SP显著降低,有统计学意义(P<0.05)。治疗各组和模型组比,肺组织中SP下降明显,肠组织中SP升高明显,有统计学意义(P<0.05)。中药低剂量组肺组织中SP含量高于地塞米松组,肠组织中SP含量低于地塞米松组,有统计学意义(P<0.05)：中药中剂量组、中药高剂量组肺、肠组织中SP含量与地塞米松组无显著差异,无统计学意义(P>0.05)；中药中剂量组、中药高剂量组肺组织中SP含量均低于中药低剂量组,肠组织中SP含量均高于中药低剂量组,有统计学意义(P<0.05)；中药高剂量组肺、肠组织中SP含量与中药中剂量组无显著差异,无统计学意义(P>0.05)。
结论：
1通腑汤可降低ALI大鼠肺组织中SP的含量,高、中剂量组效果较好。
2通腑汤可增高ALI大鼠肠组织中SP的含量,高、中剂量组效果较好。
Objective:To observe the effect on substance P(SP) in lung and intestine tissue of ALI rat model treated by Tongfu decoction, and explore the mechanisms of Tongfu decoction anti-ALI, so to provide experimental base on the lung and the large intestine being interior-exteriorly related theory.
Methods:180 Wistar rats were divided into 6 groups randomly:the normal control group, the model group, hexadecadrol group, Chinese herbal medicine low-dose group, medium-dose group, and high-dose group,30 rats each group. Copying ALI model by caudal vein injecting LPS, giving respectively the Chinese herbal medicine intragastric administration and Dexamethasone intraperitoneal injection half an hour later, and executing rats in 1,2,6 hour after treatment respectively,10 rats each time in each group. We observed lung and intestine histomorphology changes, detected SP content in lung and intestine by ELISA method synchronously.
Result:
1 Lung and intestine tissue in the model group showed dark red, turgent, bleeding by naked eye, but other treatment groups showed lighter than it.
2 Lung and intestine tissue in the model group showed inflammatory cell infiltrating, edema, hyperemia, disorganization in light microscope, but other treatment groups showed lighter.
3 SP content increased in lung tissue of the model group, while it decreased in intestine tissue as time extending in first 6 hours.
4 Compared with normal control group, There was higher SP expression in lung tissue and lower SP expression in intestine tissue in model group (P<0.05). SP decreased in lung tissue and increased in intestine tissue significantly in treatment groups Compared with model group (P<0.05). Compared with dexamethasone group,SP level is higher in lung tissue and lower in intestine tissue in low-dose group (P<0.05).In high-dose group、medium-dose group and dexamethasone group,SP level in lung and intestine tissue was similar, which showed no significant deviation (P>0.05). SP in low-dose group is higher in lung tissue and lower in intestine than high-dose and medium-dose group (P<0.05). In high-dose group、medium-dose group,SP level in lung and intestine tissue was similar, which showed no significant deviation (P>0.05).
Conclusion:
1 Tongfu Decoction could decrease SP in lung tissue of ALI rats model, the high-dose and medium-dose group showed better effects.
2 Tongfu Decoction could increase SP in intestine tissue of ALI rats model, the high-dose and medium-dose group showed better effects.
引文
[1]李玮伟,陈杰,王祥瑞等.急性肺损伤中炎性反应调节的研究进展.上海医学.2009,32(6)：550-552.
[2]Dellinger R P,Carlet J M,Masur H,et al.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med,2004,30: 536-555.
[3]Rubenfeld G D,Caldwell E,Peabodye, et al.Incidence and outcomes of acute lung injury. N Engl J Med,2005,353:1685-1693.
[4]钱桂生.急性肺损伤和急性呼吸窘迫综合征的诊断与治疗.解放军医学杂志.2009,34(4)：371-373.
[5]李明富,杨明钧,李堂圃等.中医对呼吸窘迫综合征的认识.成都中医学院学报.1980,3(1)：3-6.
[6]丁慧芬.中医肺与急性肺损伤的发病关系初探.辽宁中医杂志.2004,31(10)：823-824.
[7]肖光华,吴敏,宓越群.急性肺损伤中医病机及治法探讨.上海中医药杂志.2008,42(10)：80-82.
[8]宋志萍,师建梅.喘证辨治溯源.山西中医.2002,18(3)：1-3.
[9]宋秀明,陈晓宏.张锡纯治喘特色简论.辽宁中医学院学报.2002,4(4)：307-308.
[10]马军光,崔军,武维屏.喘证古文献研究概述.北京中医药大学学报.2001,24(4)：307-308.
[11]王今达,高天元,崔乃杰,等.祖国医学“肺与大肠相表里”学说的临床意义及其本质的探讨.中西医结合杂志.1982,2(2)：77-81.
[12]李丽娜,王庆国.从气血水探讨急性肺损伤的中医病机.北京中医药大学学报.2008,31(5)：296-298.
[13]唐洪波,陈宝国,董俊玲.从肺之化源速竭探讨ARDS辨治.江西中医药.2006,37(11)：16.
[14]耿耘,魏星.急性肺损伤、急性呼吸窘迫综合征的中医发病机理探讨.江西中医药.2002,33(5)：11-12.
[15]刘红菊,辛建保,周琼等.热毒宁注射液对急性肺损伤家兔肺表面活性物质的影响.中国新药杂志.2008,17(16)：1402-1407.
[16]刘红菊,陶晓南,辛建宝等.中药热毒宁对急性肺损伤兔肺内致炎因子的影响.中国新药与临床杂志.2007,26(6)：446-449.
[17]刘红菊,张建初,张劲农等.热毒宁注射液对兔急性肺损伤的防治作用.华中科技大学学报(医学版).2008,37(5)：610.
[18]李澎涛,张娜,朱晓磊等.痰热清注射液抗内毒素所致急性肺损伤的试验研究.中国药学杂志.2005,40(7)：518-521.
[19]吴山,盛延良,蒋志学等.丹参对大鼠肺水肿时E-选择素变化的影响.辽宁中医杂志.2003,30(3)：172-173.
[20]李敏,李锋,胡波等.丹参对大鼠急性肺损伤的保护作用.Journal of Chinese Medicinal Materials.2007,30(4):442-444.
[21]夏燕亮,刘昕.丹参对大鼠脓毒症急性肺损伤发生中TNF-α的影响及对肺的保护作用.中药药理与临床.2004,20(6)：14-17.
[22]陈畅,夏中元,王晓园等.赤芍对大鼠内毒素性急性肺损伤时iNOS和eNOS表达的影响.武汉大学学报(医学版).2005,26(1)：35-38.
[23]李玉梅,卫洪昌,汪东颖.大承气汤治疗大鼠内毒素性ARDS的疗效分析及免疫调节机制研究.中国病理生理杂志.2009,25(10)：2027-2032.
[24]金抗,于东云,由田.大黄对急性肺损伤大鼠热休克蛋白70表达的影响.中国急救医学.2007,27(9)：827-829.
[25]张远新,黄伟青,谢玉宝.参麦对内毒素型急性肺损伤家兔血清TNF-α、IL-6变化的研究.国际医药卫生导报.2009,15(22)：13-16.
[26]黄翠萍,杨和平,张珍祥.参麦注射液对脂多糖诱导大鼠急性肺损伤防护机制探讨.中华结核和呼吸杂志.2005,28(1)：67-68.
[27]曹慧玲,吕士杰,姜艳霞.中药复方参麦对大鼠急性肺损伤氧自由基的干预.中国临床康复.2006,10(23)：67-69.
[28]卫洪昌,张陈福.人参附子青皮对内毒素性休克的实验研究概况.上海中医药杂志.1989,(7)：44-46.
[29]李志文,张凤敏,莫顺景等.中西医结合治疗急性肺损伤疗效观察.中国中医急症.2004,13(9)：574-575.
[30]徐防,刘琼.痰热清注射液与无创通气联合治疗病理产科并发急性肺损伤疗效观察.中国中医急症.2009,18(1)：15-16.
[31]尹文,刘健,黄扬等.急性肺损伤发病机制和治疗现状.中国急救医学.2008,28(9)：840-842.
[32]Bernard GR,Artigas A,Brigham KL,et al.The American-european consensus conference on acute respiratory distress syndrome:definitions, mechanisms, relevant outcomes,and clinical trial coordination.Am J Respir Crit Care Med.1994, 149 (3):818-824.
[33]李玉梅,卫洪昌.ALI/ARDS抗炎治疗研究的策略与展望.中国病理生理杂志.2009,25(4)：813-816.
[34]孙海鹏,呼彩莲.急性肺损伤发病机制的研究进展.医学信息.2010,23(2)：532-533.
[35]唐镍,曹明,黄英.急性肺损伤发生机制的研究进展.检验医学与临床.2007,4(5)：398-400.
[36]施梦,祝禾辰,曹同瓦.急性肺损伤发病机制研究进展.中华急诊医学杂志.2008,17(4)：443-444.
[37]高晓玲,刘卓拉.氧自由基在急性肺损伤发病中的作用.国外医学呼吸系统分册.2002,22(6)：310-315.
[38]聂晓红,周向东.蛋白酶抑制剂对肺炎性损伤的保护作用.临床肺科杂志.2004,9(6)：665—667.
[39]高冬娜,张或.中性粒细胞弹性蛋白酶与急性肺损伤.CHINESE JOURNAL OF CRITICAL CARE MEDICINE.2006,26 (3):210-212.
[40]Kazuhito Kawabata,Tetsuya Hagio,Shozo Matsuoka.The role ofneutmphil elastase in acute lung injury.European Journal of Pharmacology.2002,451(1):1-10.
[41]Takashige Kuraki,Masayoshi Ishibashi,Masanod Takayama,et al.A novel oral neutrophil elastase inhibitor Inhibits human neutrophil elastase-induced emphysema in rats.Am J Respir Crit Care Med.2002,166:496-500.
[42]Tetsuya Hagio, Shigem Matsumoto, Shintaro Nakao, et al. Elastase inhibition reduced death associated with acid aspiration-irlduced lung injury in hamsters. European Journal of Pharmacology,2004,488:173-180.
[43]T Hagio, S Matsumoto, S Nakao, et al. Sivelestat, a specific neutrophil elastase inhibitor, prevented phorbolmyristate acetate-induced acute lung injury in conscious rabbits. Pulmonary Pharmacology & Therapeutics,2005,18:285-290.
[44]邬娇,郭曲练.急性肺损伤与细胞凋亡.中日友好医院学报.2009,23(2)：117-119.
[45]刘振千,俞森洋,刘岩.急性肺损伤大鼠肺泡内中性粒细胞凋亡的延迟.中国病理生理杂志.2003,19(5)：636-638.
[46]刘韧,肖南,田昆仑.中性粒细胞凋亡延迟在脂多糖所致大鼠急性肺损伤发病机制中的作用.中华医学杂志.2001,81(10)：617-621.
[47]蔡华荣,向小勇.炎性反应与急性肺损伤的关系研究进展.中国体外循环杂志.2006,4(2)：125-127.
[48]KazuhitoKawabata, TetsuyaHagio, ShigeruMatsumoto, et al. Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters. Am J Respir Crit Care Med.2000,161(6): 2013-2018.
[49]何晓琳,刘志,夏书月.急性呼吸窘迫综合征血管内皮损伤及凝血、纤溶系统变化的研究.中国医科大学学报.2004,33(4)：354-357.
[50]Pan J L, Xia J L, Yao L B, et al. Tumornecrosis factor of lipopolysaccharide-induced dexpression of murine P-selectin gene in endothelia cells incolves novel κB sites and a variantactivating transcription factor/Camp response element. J Biol Chem,1998,273 (16):10068-10077.
[51]Petraehel, BirukovaA, Ramirez S. et al. The role of the Mierotubules In Tumor Necrosis Factor-alpha-induced endo-thelial cell permeability. Am J Respir Cell Mol Biol,2003,28 (5):574-581.
[52]DELCLAUX C, L'HER E, ALBERTI C, et al. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask:A randomized controlledtrial. JAMA,2000,284: 2352-2360.
[53]中华医学会重症医学分会.急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006).医学与哲学.2007,28(2)：19-28.
[54]孟激光,段蕴铀.急性肺损伤及急性呼吸窘迫综合征机械通气治疗进展.海军总医院学报.2006,19(4)：232-236.
[55]Hudson LD. Progress in understanding ventilator-inducedlunginjury. JAMA.1999, 282(1):77.
[56]上海市肺科学会中青年学组.机械通气相关性肺损伤及其对策.中华结核和呼吸杂志.2002,25：182-184.
[57]崔乃杰.急性呼吸窘迫综合征的新进展.中华急诊医学杂志.2001,10(5)：356-358.
[58]钱桂生,王建春.急性呼吸窘迫综合征研究进展.第三军医大学学报.2004,26(10)：842-844.
[59]Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of acute lung injury. Pulm Pharmacol Ther.2002,15:83-95.
[60]韩力,时国朝,李庆云.急性肺损伤/急性呼吸窘迫综合征药物治疗进展.国际呼吸志.2007,27(5)：333-337.
[61]Groeneveld A B. Vascular pharmacology of acute lung injury and acute respiratory distress syndrome. Vascul Pharmacol.2003,39(4-5):247-256.
[62]周吕.胃肠生理学.北京：科学技术出版社,1991：726-727.
[63]匡调元.中医病理研究.上海：科学技术出版社,1980：145.
[64]赵棣华.中西医结合探脏腑.成都：四川科学技术出版社,1984：20.
[65]潘晓明,段晓慧.肺的非呼吸功能与中医肺脏相关性探析.甘肃中医.1993,6(3)：1-3.
[66]刘进.血管活性肠肽与呼吸系统.国外医学呼吸系统分册.1995,15(1)：27.
[67]靳文学,杨宇.从黏膜免疫系统看“肺与大肠相表里”.四川中医.2005,23(12)：1-3.
[68]王今达.祖国医学“肺与大肠相表里”学说的临床意义及其本质的探讨.中西医结合杂志.1982,2(2)：77.
[69]李风森.氧化-抗氧化与哮喘及肺与大肠关系的研究.上海中医药大学硕士.1994：27.
[70]杜丽娟.“肺与大肠相表里”与哮喘黏膜免疫中CD4+、CDs+T淋巴细胞关系的研究.新疆医科大学硕士.2008：22.
[71]李春盛,桂培春,何新华等.大黄对内毒素诱导急性肺损伤大鼠的保护作用.基础医学与临床.2001,21(1)：65-68.
[72]廖荣鑫,黄礼明,吴仕九.肺病治肠在慢性肺心病急性发作期中的运用.辽宁中医杂志.2004,31(6)：461-462.
[73]杨胜兰,王鹏,李道本等.通腑法对大鼠肠源性肺损伤保护作用机制的研究.Chin J Integr Trad West Med Dig.2003,11(3):154-156.
[74]谢晓华,张晓清,杨银芬等.通腑泻热方治疗胸科急性肺损伤的临床观察.新中医.2008,40(8)：45-46.
[75]郑瞬华,崔儒涛.补肺方抗实验性溃疡性结肠炎大鼠脂质过氧化损伤的研究.中国中医药科技.1999,6(4)：231-232.
[76]张小军.慢性肠炎从肺论治.陕西中医.1996,17(7)：336.
[77]宋勉,王亚梅.肺肠同治法在治疗支气管哮喘急性发作期的运用.光明中医.2005,20(1)：5-6.
[78]白亚辉,陈辉,杨宇.肺肠合治法对哮喘小鼠血清总IgE影响的实验研究.中华中医药学刊.2007,25(6)：1131-1133.
[79]刘迎迎.P物质在急性胰腺炎相关肺损伤中的作用.河北医科大学硕士.2008：45.
[80]O'Connor, T. M, J. O'Connell, D, et al. The role of substance P in inflammatory disease. Cell.Physiol.2004,201:167-180.
[81]Ho, W. Z, J. P. Lai, X. H. Zhu, M.Uvaydova,and S.D.Douglas.Human monocytes and macrophages express substance P and neurokinin-1 receptor.J.Jmmunol.1997,159: 5654-5660.
[82]Lai, J. P. S. D. Douglas, and W. Z. Ho. Human lymphocytes express substance P and its receptor.J.Neuroimmunol.1998,86:80-86.
[83]王秀萍,郭政.P物质与呼吸道炎症.《国外医学》麻第醉学与复苏分册.2005,26(6)：321-324.
[84]孙宏伟,任广睦,高彩荣.P物质与炎性疾病研究进展.山西医科大学学报.2005,36(2)：257-260.
[85]Groneberg, D. A., S. Harrison, Q. T. Dinh, P. Geppetti, and A. Fischer. Tachykinins in the respiratory tract. Curr.Drug Targets.2006,7:1005-1010.
[86]Gibson M S, Johnson A C. NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol Biochem Behav,2003,74 (4): 1005-13.
[87]王丽凤,张尚俭,司军强等.P物质在非中枢神经系统中的作用.石河子大学学报(自然科学版).2003,7(4)：336-340.
[88]方富贵,章孝荣.P物质研究进展.动物医学进展.2005,26(1)：6-8.
[89]杜立峰,展淑琴,郭新奎.P物质、血管活性肠肽与异常胃肠通过的关系.西安交通大学学报(医学版).2003,24(4)：365-376.
[90]Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol.2004,202 (2):145-156.
[91]马春蕾.P物质在大鼠重症急性胰腺炎相关性肺损伤中的作用.天津医科大学硕士.2007：21.
[92]张劭博,邹最,石学银.P物质在异氟烷诱发脊髓损伤大鼠神经源性肺水肿中的作用.中国矫形外科杂志.2009,17(10)：774-776.
[93]Selena Wei Shan Sio, Manoj Kumar Puthia, Jia Lu, Shabbir Moochhala, and Madhav BhatiaThe Neuropeptide Substance P Is a Critical Mediator of Burn-Induced Acute Lung Injury.Immunol.2008,180:8333-8341.
[94]Groneberg, D. A., D. Quarcoo, N. Frossard, and A. Fischer. Neurogenic mechanisms in bronchial inflammatory diseases.Allergy.2004.59:1139-1152.
[95]胡浩霖,石欣,霍明东.P物质受体拮抗剂对急性坏死性胰腺炎时肺损伤保护作用的实验研究.东南大学学报(医学版),2007,26(3)：174-177.
[96]Chanez P, Springall D, Vignola AM. Bronchial mucosalimmunoreactivity of sensory neuropeptides in severe airway disease. Am Respir Crit Care Med,1998, 158:985-990.
[97]姜明,李玉.慢性阻塞性肺疾病患者中央气道P物质、血管活性肠肽的分布及其意义.2001,41(20)：1-3.
[98]王倩,范文涛,周永学.硝菔通结颗粒对老年便秘大鼠肠组织P物质、血管活性肠肽含量的影响.陕西中医学院学报.2007,30(3)：38-39·
[99]Menzies JR, Mckee R, Corbett AD. Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation. Regul Pept,2001,99(2/3):151-156.
[100]夏顺,刘希双,鞠辉.肠易激综合征患者肠黏膜SP、SPR和5-HT的变化.世界华人消化杂志,2009,17(30)：3169-3173.
[101]陈晓敏,张燕华,毛峻岭.肠易激综合征患者结肠黏膜P物质、血管活性肠肽和肥大细胞的变化.Chin J Gastroenterol.2008,13 (4):228-230.
[102]史洪涛,桂先勇,冷恩仁.内毒素血症大鼠肠道NO、SP变化的实验研究.中国急救医学.2000,20(12)：703-704.
[103]Lordal M, Johansson C, Hellstrom PM.Myoelectric pattern and effects on small bowel transit induced by the tachykinins neurokinin A, neurokinin B, substance P and neuropeptide K in the rat. J Gastrointest Motil,1993,5:33-40.
[104]季淑梅,赵文爱,胡圣爱.P物质的研究概况.医学动物防制.1999,15(5)：278-280.
[105]Pascual DW. The role of tachykinins on bacterial infections. Front Biosci,2004, 9:3209-3217.
[106]赖少彤,缪丹,鲍秀琦.柴芩承气汤对实验性坏死性胰腺炎肠道屏障保护作用的实验研究.中华医学实践杂志.2003,2(2)：100-102.
[107]祝利,司军强,赵磊.SP在伤害性信息传递过程中的作用.农垦医学.2007,5(29)：360-363.
[108]张世红,赵晏.P物质的免疫调节作用.生理科学进展.2002,33(3)：235-238.
[109]周武庆,李义梅.P物质与炎症研究进展.国外医学免疫学分册.1997,(2)：95-98.
[110]张晖,周国华.P物质与炎症性肠病的研究现状.实用医学杂志.2009,25(1)：160-162.
[111]赵琪,崔乃强,吴咸中等.MODS患者外周血单核细胞炎性细胞因子分泌及下法影响.河北中西医结合杂志.1998,7(5)：657.
[112]陈海龙,刘艳,吴咸中等.多器官功能不全综合征时肠道细菌易位及通里攻下法影响的实验研究.中国微生态学杂志.1998,10(6)：342-346.
[113]施梦,曹同瓦,沈蕾等.依达拉奉对脓毒症大鼠的保护作用研究.中国危重病急救医学.2009,21(12)：747-748.
[2]Dellinger R P,Carlet J M,Masur H,et al.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med,2004,30: 536-555.
[3]Rubenfeld G D,Caldwell E,Peabodye, et al.Incidence and outcomes of acute lung injury. N Engl J Med,2005,353:1685-1693.
[4]钱桂生.急性肺损伤和急性呼吸窘迫综合征的诊断与治疗.解放军医学杂志.2009,34(4)：371-373.
[5]李明富,杨明钧,李堂圃等.中医对呼吸窘迫综合征的认识.成都中医学院学报.1980,3(1)：3-6.
[6]丁慧芬.中医肺与急性肺损伤的发病关系初探.辽宁中医杂志.2004,31(10)：823-824.
[7]肖光华,吴敏,宓越群.急性肺损伤中医病机及治法探讨.上海中医药杂志.2008,42(10)：80-82.
[8]宋志萍,师建梅.喘证辨治溯源.山西中医.2002,18(3)：1-3.
[9]宋秀明,陈晓宏.张锡纯治喘特色简论.辽宁中医学院学报.2002,4(4)：307-308.
[10]马军光,崔军,武维屏.喘证古文献研究概述.北京中医药大学学报.2001,24(4)：307-308.
[11]王今达,高天元,崔乃杰,等.祖国医学“肺与大肠相表里”学说的临床意义及其本质的探讨.中西医结合杂志.1982,2(2)：77-81.
[12]李丽娜,王庆国.从气血水探讨急性肺损伤的中医病机.北京中医药大学学报.2008,31(5)：296-298.
[13]唐洪波,陈宝国,董俊玲.从肺之化源速竭探讨ARDS辨治.江西中医药.2006,37(11)：16.
[14]耿耘,魏星.急性肺损伤、急性呼吸窘迫综合征的中医发病机理探讨.江西中医药.2002,33(5)：11-12.
[15]刘红菊,辛建保,周琼等.热毒宁注射液对急性肺损伤家兔肺表面活性物质的影响.中国新药杂志.2008,17(16)：1402-1407.
[16]刘红菊,陶晓南,辛建宝等.中药热毒宁对急性肺损伤兔肺内致炎因子的影响.中国新药与临床杂志.2007,26(6)：446-449.
[17]刘红菊,张建初,张劲农等.热毒宁注射液对兔急性肺损伤的防治作用.华中科技大学学报(医学版).2008,37(5)：610.
[18]李澎涛,张娜,朱晓磊等.痰热清注射液抗内毒素所致急性肺损伤的试验研究.中国药学杂志.2005,40(7)：518-521.
[19]吴山,盛延良,蒋志学等.丹参对大鼠肺水肿时E-选择素变化的影响.辽宁中医杂志.2003,30(3)：172-173.
[20]李敏,李锋,胡波等.丹参对大鼠急性肺损伤的保护作用.Journal of Chinese Medicinal Materials.2007,30(4):442-444.
[21]夏燕亮,刘昕.丹参对大鼠脓毒症急性肺损伤发生中TNF-α的影响及对肺的保护作用.中药药理与临床.2004,20(6)：14-17.
[22]陈畅,夏中元,王晓园等.赤芍对大鼠内毒素性急性肺损伤时iNOS和eNOS表达的影响.武汉大学学报(医学版).2005,26(1)：35-38.
[23]李玉梅,卫洪昌,汪东颖.大承气汤治疗大鼠内毒素性ARDS的疗效分析及免疫调节机制研究.中国病理生理杂志.2009,25(10)：2027-2032.
[24]金抗,于东云,由田.大黄对急性肺损伤大鼠热休克蛋白70表达的影响.中国急救医学.2007,27(9)：827-829.
[25]张远新,黄伟青,谢玉宝.参麦对内毒素型急性肺损伤家兔血清TNF-α、IL-6变化的研究.国际医药卫生导报.2009,15(22)：13-16.
[26]黄翠萍,杨和平,张珍祥.参麦注射液对脂多糖诱导大鼠急性肺损伤防护机制探讨.中华结核和呼吸杂志.2005,28(1)：67-68.
[27]曹慧玲,吕士杰,姜艳霞.中药复方参麦对大鼠急性肺损伤氧自由基的干预.中国临床康复.2006,10(23)：67-69.
[28]卫洪昌,张陈福.人参附子青皮对内毒素性休克的实验研究概况.上海中医药杂志.1989,(7)：44-46.
[29]李志文,张凤敏,莫顺景等.中西医结合治疗急性肺损伤疗效观察.中国中医急症.2004,13(9)：574-575.
[30]徐防,刘琼.痰热清注射液与无创通气联合治疗病理产科并发急性肺损伤疗效观察.中国中医急症.2009,18(1)：15-16.
[31]尹文,刘健,黄扬等.急性肺损伤发病机制和治疗现状.中国急救医学.2008,28(9)：840-842.
[32]Bernard GR,Artigas A,Brigham KL,et al.The American-european consensus conference on acute respiratory distress syndrome:definitions, mechanisms, relevant outcomes,and clinical trial coordination.Am J Respir Crit Care Med.1994, 149 (3):818-824.
[33]李玉梅,卫洪昌.ALI/ARDS抗炎治疗研究的策略与展望.中国病理生理杂志.2009,25(4)：813-816.
[34]孙海鹏,呼彩莲.急性肺损伤发病机制的研究进展.医学信息.2010,23(2)：532-533.
[35]唐镍,曹明,黄英.急性肺损伤发生机制的研究进展.检验医学与临床.2007,4(5)：398-400.
[36]施梦,祝禾辰,曹同瓦.急性肺损伤发病机制研究进展.中华急诊医学杂志.2008,17(4)：443-444.
[37]高晓玲,刘卓拉.氧自由基在急性肺损伤发病中的作用.国外医学呼吸系统分册.2002,22(6)：310-315.
[38]聂晓红,周向东.蛋白酶抑制剂对肺炎性损伤的保护作用.临床肺科杂志.2004,9(6)：665—667.
[39]高冬娜,张或.中性粒细胞弹性蛋白酶与急性肺损伤.CHINESE JOURNAL OF CRITICAL CARE MEDICINE.2006,26 (3):210-212.
[40]Kazuhito Kawabata,Tetsuya Hagio,Shozo Matsuoka.The role ofneutmphil elastase in acute lung injury.European Journal of Pharmacology.2002,451(1):1-10.
[41]Takashige Kuraki,Masayoshi Ishibashi,Masanod Takayama,et al.A novel oral neutrophil elastase inhibitor Inhibits human neutrophil elastase-induced emphysema in rats.Am J Respir Crit Care Med.2002,166:496-500.
[42]Tetsuya Hagio, Shigem Matsumoto, Shintaro Nakao, et al. Elastase inhibition reduced death associated with acid aspiration-irlduced lung injury in hamsters. European Journal of Pharmacology,2004,488:173-180.
[43]T Hagio, S Matsumoto, S Nakao, et al. Sivelestat, a specific neutrophil elastase inhibitor, prevented phorbolmyristate acetate-induced acute lung injury in conscious rabbits. Pulmonary Pharmacology & Therapeutics,2005,18:285-290.
[44]邬娇,郭曲练.急性肺损伤与细胞凋亡.中日友好医院学报.2009,23(2)：117-119.
[45]刘振千,俞森洋,刘岩.急性肺损伤大鼠肺泡内中性粒细胞凋亡的延迟.中国病理生理杂志.2003,19(5)：636-638.
[46]刘韧,肖南,田昆仑.中性粒细胞凋亡延迟在脂多糖所致大鼠急性肺损伤发病机制中的作用.中华医学杂志.2001,81(10)：617-621.
[47]蔡华荣,向小勇.炎性反应与急性肺损伤的关系研究进展.中国体外循环杂志.2006,4(2)：125-127.
[48]KazuhitoKawabata, TetsuyaHagio, ShigeruMatsumoto, et al. Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters. Am J Respir Crit Care Med.2000,161(6): 2013-2018.
[49]何晓琳,刘志,夏书月.急性呼吸窘迫综合征血管内皮损伤及凝血、纤溶系统变化的研究.中国医科大学学报.2004,33(4)：354-357.
[50]Pan J L, Xia J L, Yao L B, et al. Tumornecrosis factor of lipopolysaccharide-induced dexpression of murine P-selectin gene in endothelia cells incolves novel κB sites and a variantactivating transcription factor/Camp response element. J Biol Chem,1998,273 (16):10068-10077.
[51]Petraehel, BirukovaA, Ramirez S. et al. The role of the Mierotubules In Tumor Necrosis Factor-alpha-induced endo-thelial cell permeability. Am J Respir Cell Mol Biol,2003,28 (5):574-581.
[52]DELCLAUX C, L'HER E, ALBERTI C, et al. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask:A randomized controlledtrial. JAMA,2000,284: 2352-2360.
[53]中华医学会重症医学分会.急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006).医学与哲学.2007,28(2)：19-28.
[54]孟激光,段蕴铀.急性肺损伤及急性呼吸窘迫综合征机械通气治疗进展.海军总医院学报.2006,19(4)：232-236.
[55]Hudson LD. Progress in understanding ventilator-inducedlunginjury. JAMA.1999, 282(1):77.
[56]上海市肺科学会中青年学组.机械通气相关性肺损伤及其对策.中华结核和呼吸杂志.2002,25：182-184.
[57]崔乃杰.急性呼吸窘迫综合征的新进展.中华急诊医学杂志.2001,10(5)：356-358.
[58]钱桂生,王建春.急性呼吸窘迫综合征研究进展.第三军医大学学报.2004,26(10)：842-844.
[59]Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of acute lung injury. Pulm Pharmacol Ther.2002,15:83-95.
[60]韩力,时国朝,李庆云.急性肺损伤/急性呼吸窘迫综合征药物治疗进展.国际呼吸志.2007,27(5)：333-337.
[61]Groeneveld A B. Vascular pharmacology of acute lung injury and acute respiratory distress syndrome. Vascul Pharmacol.2003,39(4-5):247-256.
[62]周吕.胃肠生理学.北京：科学技术出版社,1991：726-727.
[63]匡调元.中医病理研究.上海：科学技术出版社,1980：145.
[64]赵棣华.中西医结合探脏腑.成都：四川科学技术出版社,1984：20.
[65]潘晓明,段晓慧.肺的非呼吸功能与中医肺脏相关性探析.甘肃中医.1993,6(3)：1-3.
[66]刘进.血管活性肠肽与呼吸系统.国外医学呼吸系统分册.1995,15(1)：27.
[67]靳文学,杨宇.从黏膜免疫系统看“肺与大肠相表里”.四川中医.2005,23(12)：1-3.
[68]王今达.祖国医学“肺与大肠相表里”学说的临床意义及其本质的探讨.中西医结合杂志.1982,2(2)：77.
[69]李风森.氧化-抗氧化与哮喘及肺与大肠关系的研究.上海中医药大学硕士.1994：27.
[70]杜丽娟.“肺与大肠相表里”与哮喘黏膜免疫中CD4+、CDs+T淋巴细胞关系的研究.新疆医科大学硕士.2008：22.
[71]李春盛,桂培春,何新华等.大黄对内毒素诱导急性肺损伤大鼠的保护作用.基础医学与临床.2001,21(1)：65-68.
[72]廖荣鑫,黄礼明,吴仕九.肺病治肠在慢性肺心病急性发作期中的运用.辽宁中医杂志.2004,31(6)：461-462.
[73]杨胜兰,王鹏,李道本等.通腑法对大鼠肠源性肺损伤保护作用机制的研究.Chin J Integr Trad West Med Dig.2003,11(3):154-156.
[74]谢晓华,张晓清,杨银芬等.通腑泻热方治疗胸科急性肺损伤的临床观察.新中医.2008,40(8)：45-46.
[75]郑瞬华,崔儒涛.补肺方抗实验性溃疡性结肠炎大鼠脂质过氧化损伤的研究.中国中医药科技.1999,6(4)：231-232.
[76]张小军.慢性肠炎从肺论治.陕西中医.1996,17(7)：336.
[77]宋勉,王亚梅.肺肠同治法在治疗支气管哮喘急性发作期的运用.光明中医.2005,20(1)：5-6.
[78]白亚辉,陈辉,杨宇.肺肠合治法对哮喘小鼠血清总IgE影响的实验研究.中华中医药学刊.2007,25(6)：1131-1133.
[79]刘迎迎.P物质在急性胰腺炎相关肺损伤中的作用.河北医科大学硕士.2008：45.
[80]O'Connor, T. M, J. O'Connell, D, et al. The role of substance P in inflammatory disease. Cell.Physiol.2004,201:167-180.
[81]Ho, W. Z, J. P. Lai, X. H. Zhu, M.Uvaydova,and S.D.Douglas.Human monocytes and macrophages express substance P and neurokinin-1 receptor.J.Jmmunol.1997,159: 5654-5660.
[82]Lai, J. P. S. D. Douglas, and W. Z. Ho. Human lymphocytes express substance P and its receptor.J.Neuroimmunol.1998,86:80-86.
[83]王秀萍,郭政.P物质与呼吸道炎症.《国外医学》麻第醉学与复苏分册.2005,26(6)：321-324.
[84]孙宏伟,任广睦,高彩荣.P物质与炎性疾病研究进展.山西医科大学学报.2005,36(2)：257-260.
[85]Groneberg, D. A., S. Harrison, Q. T. Dinh, P. Geppetti, and A. Fischer. Tachykinins in the respiratory tract. Curr.Drug Targets.2006,7:1005-1010.
[86]Gibson M S, Johnson A C. NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol Biochem Behav,2003,74 (4): 1005-13.
[87]王丽凤,张尚俭,司军强等.P物质在非中枢神经系统中的作用.石河子大学学报(自然科学版).2003,7(4)：336-340.
[88]方富贵,章孝荣.P物质研究进展.动物医学进展.2005,26(1)：6-8.
[89]杜立峰,展淑琴,郭新奎.P物质、血管活性肠肽与异常胃肠通过的关系.西安交通大学学报(医学版).2003,24(4)：365-376.
[90]Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol.2004,202 (2):145-156.
[91]马春蕾.P物质在大鼠重症急性胰腺炎相关性肺损伤中的作用.天津医科大学硕士.2007：21.
[92]张劭博,邹最,石学银.P物质在异氟烷诱发脊髓损伤大鼠神经源性肺水肿中的作用.中国矫形外科杂志.2009,17(10)：774-776.
[93]Selena Wei Shan Sio, Manoj Kumar Puthia, Jia Lu, Shabbir Moochhala, and Madhav BhatiaThe Neuropeptide Substance P Is a Critical Mediator of Burn-Induced Acute Lung Injury.Immunol.2008,180:8333-8341.
[94]Groneberg, D. A., D. Quarcoo, N. Frossard, and A. Fischer. Neurogenic mechanisms in bronchial inflammatory diseases.Allergy.2004.59:1139-1152.
[95]胡浩霖,石欣,霍明东.P物质受体拮抗剂对急性坏死性胰腺炎时肺损伤保护作用的实验研究.东南大学学报(医学版),2007,26(3)：174-177.
[96]Chanez P, Springall D, Vignola AM. Bronchial mucosalimmunoreactivity of sensory neuropeptides in severe airway disease. Am Respir Crit Care Med,1998, 158:985-990.
[97]姜明,李玉.慢性阻塞性肺疾病患者中央气道P物质、血管活性肠肽的分布及其意义.2001,41(20)：1-3.
[98]王倩,范文涛,周永学.硝菔通结颗粒对老年便秘大鼠肠组织P物质、血管活性肠肽含量的影响.陕西中医学院学报.2007,30(3)：38-39·
[99]Menzies JR, Mckee R, Corbett AD. Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation. Regul Pept,2001,99(2/3):151-156.
[100]夏顺,刘希双,鞠辉.肠易激综合征患者肠黏膜SP、SPR和5-HT的变化.世界华人消化杂志,2009,17(30)：3169-3173.
[101]陈晓敏,张燕华,毛峻岭.肠易激综合征患者结肠黏膜P物质、血管活性肠肽和肥大细胞的变化.Chin J Gastroenterol.2008,13 (4):228-230.
[102]史洪涛,桂先勇,冷恩仁.内毒素血症大鼠肠道NO、SP变化的实验研究.中国急救医学.2000,20(12)：703-704.
[103]Lordal M, Johansson C, Hellstrom PM.Myoelectric pattern and effects on small bowel transit induced by the tachykinins neurokinin A, neurokinin B, substance P and neuropeptide K in the rat. J Gastrointest Motil,1993,5:33-40.
[104]季淑梅,赵文爱,胡圣爱.P物质的研究概况.医学动物防制.1999,15(5)：278-280.
[105]Pascual DW. The role of tachykinins on bacterial infections. Front Biosci,2004, 9:3209-3217.
[106]赖少彤,缪丹,鲍秀琦.柴芩承气汤对实验性坏死性胰腺炎肠道屏障保护作用的实验研究.中华医学实践杂志.2003,2(2)：100-102.
[107]祝利,司军强,赵磊.SP在伤害性信息传递过程中的作用.农垦医学.2007,5(29)：360-363.
[108]张世红,赵晏.P物质的免疫调节作用.生理科学进展.2002,33(3)：235-238.
[109]周武庆,李义梅.P物质与炎症研究进展.国外医学免疫学分册.1997,(2)：95-98.
[110]张晖,周国华.P物质与炎症性肠病的研究现状.实用医学杂志.2009,25(1)：160-162.
[111]赵琪,崔乃强,吴咸中等.MODS患者外周血单核细胞炎性细胞因子分泌及下法影响.河北中西医结合杂志.1998,7(5)：657.
[112]陈海龙,刘艳,吴咸中等.多器官功能不全综合征时肠道细菌易位及通里攻下法影响的实验研究.中国微生态学杂志.1998,10(6)：342-346.
[113]施梦,曹同瓦,沈蕾等.依达拉奉对脓毒症大鼠的保护作用研究.中国危重病急救医学.2009,21(12)：747-748.